ΚΑΡΚΙΝΟΣ ΩΟΘΗΚΩΝ - ΣΥΓΧΡΟΝΕΣ ΑΠΟΨΕΙΣ
Περίληψη
No AbstractΑναφορές
Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992; 339: 1-15, 71-85.
Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. Ν. Engl. J Med. 1988; 319: 1681-1692.
Fisher Β , Redmond G, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment οf positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin. Oncol. 1990; 8: 1005-1018.
Pritchard ΚΙ, Zee Β, Paul Ν, et al. CMF added to tamoxifen as adjuvant therapy in post-menopausal women with node-positive (+VE) estrogen (ER) and/or progesterone receptor (PgR) +VE breast cancer: negative results from a randomized clinical trial. Proc Am Soc Oncol. 1994; 13: 65.
Levine ΜΝ, Gent Μ, Hirsh J, et al. The trhombogenic effect of anticancer drug therapy in women with stage ΙΙ breast cancer. Ν. Engl J Med. 1988; 318: 404-407.
Pritchard ΚΙ, Pater J, Paul Ν, et al. Thromboembolic complications related to chemotherapy. Proc Am Soc Clin Oncol. 1988; 8: 25. Abstract.
Olivotto ΙΑ, Bajdik CD, Math Μ, et al. Adjuvant systemic therapy and surνival after breast cancer. Ν Engl J Med. 1994; 330: 805-810.
Clark GM, McGuire Ι. Defining the high-risk breast cancer patient. In: Henderson IC, ed. Adjuvant Therapy of Breast Cancer. Norwell, Mass: Kluwer Academic; 1992: 161-187.
Henderson IC. Prognostic facrors. Ιn: Harris JR, Hellman S, Henderson JC, eds. Breast Diseases, 2nd ed. Philadelphia, Pa: JB Lippincott; 1991: 332-346.
Nemoto Τ, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980; 45: 2917-2924.
Carter CL, Allen G, Henson DΕ. Relation of tumor size, lymph node status, and survival in 24.740 breast cancer cases. Cancer. 1989; 63: 181-187.
Fisher Β , Redmond C, Fisher ER, et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988; 6: 1076-1087.
Clark GM, Dressler LG, Owens ΜΑ, et al. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. Ν Engl J Med 198; 320: 627-633.
Silvestrini R, Daidone MG, DiFronzo G, et al. Prognostic implication of labeling index νersus estrogen receptors and tumor size in node negative breast cancer. Breast Cancer Res Treat. 1986; 7: 161-169.
Allred DC, Clark GM. Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993; 85: 200-206.
Weidner Ν, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875- 1887.
Gelber RD, Goldhirsch Α, Hurny G, et al. Quality of life in clinical trials of adjuvant therapies. J Natl Cancer Inst Monogr. 1992; 11: 127-135.
Levine MN, Gafni Α, Markham Β, et al. Α bedside decision instrument to clicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 1992; 117: 53-58.
Wood WC, Budman DR, Korzum ΑΗ, et al. Dose and dose intensity of adjuvant chemotherapy fοr stage ΙΙ, node-positive breast carcinoma. Ν Engl J Med. 1994; 330: 1253-1259.
Muss ΗΒ, Τhοr AD, Berry DΑ, et al. c-erb Β-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. Ν Engl J Med. 1994; 330: 1260-1266.
Toikkanen S, Helin Η, Isola J, et al. Prognostic significance or HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992; 10: 1044-1048.
Gusterson ΒΑ, Gelber RD, Goldhirsch Α, et al. Prognostic importance of c-erB-2 expression in breast cancer. J Clin Oncol. 1992; 10: 1049-1056.
Levine ΜΝ, Andrulis 1. The Ηer-2/ neu oncogene in breast cancer: so what is new? J Clin Oncol. 1992; 10: 1034-1036.
Bonadonna G, Valagussa Ρ. Dose response effect of adjuvant chemotherapy in breast cancer. Ν Engl J Med. 1981; 304: 10-15.
Levine ΜΝ, Gent Μ, Hryniuk WM, et al. Α randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage ΙΙ breast cancer. J Clin Oncol. 1990; 8: 1217-1225.
Falkson HC, Gray R, Wolberg WH, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continous tamoxifen versus four cycles or CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group Phase ΙΙΙ Study. J Clin Oncol. 1990; 8: 599-607.
Fisher Β, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86: 527-537.
Italian Multicentre BΓeast Study With Epirubicin. Phase ΙΙΙ randomized study of fluorouracil, epirubicin, and cyclophosphamide ν fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian Multicentre Trial J Clin Oncol. 1988; 6: 976-982.
French Epirubicin Study Group. Α prospective randomized phase ΙΙΙ trial comparing combination chemorherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol. 1988; 6: 679-688.
Buzzoni R, Bonadonna G. Valagussa Ρ, et al. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methorexate, and fluorouracil in the treatment of rescetable breast cancer with more than three positive axillary nodes. J Clin Oncol. 1991; 9: 2134-2140.
Dimitrov Ν, Anderson S, Fisher Β, et al. Dose-intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): Findings from NSA-BP-22. Ρroc Am Soc Clin Oncol. 1994; 13: 64.
Levine ΜΝ, Bramwell V, Pritchard Κ, et al. Α pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. Eur J Cancer. 1993; 29Α: 37-43.
Bonadonna G, Valagussa Ρ, Brambilla G, et al. Response to primary chemotherapy (PC) increases rates of breast preservation and correlates with prognosis. Proc Αm Soc Clin Oncol. 1994; 13: 107.
Fisher Β, Rockette Η, Robidoux Α, et al. Effect of preoperative therapy for breast cancer (BC) on local-regional disease: first report of NSABP Β-18. Ρroc Am Soc Clin Oncol. 1994; 13: 64.
Bonadonna G. High risk breast cancer: from adjuvant to neoadjuvant chemotherapy. In: Fortner JG, Rhoads JE, eds. Accomplishment in Cancer Research. General Motors Cancer Rescarch Foundation. Philadelphia, Pa: JB Lippincott Co; 1994. In press.
Peters WP, Ross Μ, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy fοr high risk primary breast cancer. J Clin Oncol. 1993; 11: 1132-1143.
Arbuck SG, Dοrr Α, Friedman ΜΑ. Paelitaxel (Taxol) in breast cancer. Hematol Clin North Am. 1994; 8: 121-140.
Gianni L, Stranco Μ, Capri G, et al. Optimal dose and sequence finding study of paelitaxel by 3 h infusion combined with bolus doxorubicin in untreated metastatic breast cancer patients. Ρroc Am Soc Clin Oncol. 199: 74.
Levine ΜΝ, Guyatt GH, Gent Μ, et al. Quality οf life in stage ΙΙ breast cancer: an instrument fοr clinical trials. J Clin Oncol. 1988; 6: 1798-1810.
Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer - associated hypercalcaemia. Lancet 1989; ii: 1180-82.
Purohit ΟΡ, Anthony C, Owen J, et al. Randomised double-blind comparison of single infusions of pamidronate or clodronate fοr hypercalcaemia of malignancy. Βr J Cancer 1994; 69 (suppl ΧΧΙ): 10.
Paterson AHG, Powles TJ, Kanis JA, et al. Double blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993; 11: 59-65.
van Holten-Verzantvoort ΑΤ, Kroon ΗΜ, Bijvoet OLM, et al. Palliative bone treatment in patients with bone metastases from breast cancer. J Clin Oncol. 1993; 11: 491-498.
Doll R. An overview of the epidemiological evidence linking diet and cancer., Ρroc Nutr Soc 1990; 49: 119-31.
Wynder EL. Cancer prevention: optimizing life-styles with special reference to nutritional carcinogenesis. J Nat Cancer Inst Monogr 1992; 12: 87-91.
Bal DG, Foerster SB. Dietary strategies fοr cancer prevention. Cancer 1993; 72 (suppl): 1005-10.
Lutz WK, Schlatter J. The relative importance of mutagens and carcinogens in the diet. Pharmacol Toxicol 1993; 72 (1), S104-7.
AustokeΓ J. Cancer prevention in primary care: Diet and cancer. Βr Med J 1994; 308: 1610-14.
Adami Η-O, Dragsted L, Enig Β, et al. Report from the Working Group on Diet and Cancer. Pharmacol Toxicol 1993; 72 (Suppl 1): S176-9.
Nestle Μ. Dietary recommendations for cancer prevention: pyblic policy implemenιation. J Nat Cancer Inst Monogr. 1992; 12: 153-7.
Fallowfield LJ, Hall Α, Maguire GP, et al. Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. Br Med J 1990; 30: 575-80.
Fisher Β, Bauer Μ, Wickerham DL, et al. Relation of the number of positive axillary lymph nodes to the prognosis of patients with primary breast cancer. Cancer 1983; 52: 1551-7.
Bates Τ, Riley DL, Houghton J, et al. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br J Surg 1991; 78: 591-4.
Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy. Lancet 1992; 339: 1-15 , 71-85.
Fisher Β, Cosrantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Β-14 , J Nat Canc Inst 1994; 86 (7): 527-31.
World Health Organization. Cancer Relief and Palliative Care. Report οf a WHO Expert Committee. WHO Technical Report Series, No. 804, Geneva, Switzerland (1990).
George Manolakis. Lectures in clinical oncology. Medical University of Southern Africa Department of Internal Medicine Oncology Unit. MEDUNSA: 1995.
Pacitaxel (Taxol) in gynecologic malignancies. International Journal of Gynecological Cancer. Vol 4, Supplement 1, November / December 1994. Proceedings of a satelite symposium of the Fourth Biennial Meeting of the International Gynecological Cancer Society held in Stockholm, Sweden.
